null - FindTrial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2012-004408-36-FR

Enrollment

Registered

2013-06-12

Start date

2013-03-12

Completion date

Unknown

Last updated

2025-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

_ MedDRA version: 14.1 Level: LLT Classification code 10051975 Term: Salivary gland carcinoma System Organ Class: 100000004864

Interventions

Trade Name: Votrient Pharmaceutical Form: Tablet INN or Proposed INN: PAZOPANIB CAS Number: 444731-52-6 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200-

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: _ Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 32 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 31

Exclusion criteria

Exclusion criteria: _

Design outcomes

Primary

Measure	Time frame
Main Objective: _;Secondary Objective: _;Primary end point(s): _;Timepoint(s) of evaluation of this end point: _	—

Secondary

Measure	Time frame
Secondary end point(s): _;Timepoint(s) of evaluation of this end point: _	—

Countries

France

Contacts

Public ContactKarine BUFFARD

UNICANCER

k-buffard@unicancer.fr01 44 23 55 77

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026